Danoprevir, also known as ITMN-191 and RG-7227, is under development by InterMune Inc and Roche Holding AG, is a promising, potent NS3/4A protease inhibitor for the oral treatment of HCV infection. Preclinical data demonstrated that danoprevir binds with high affinity and dissociates slowly from the HCV NS3 protease, allowing high liver drug exposure with only modest plasma drug exposure. A phase Ib, 'IFN-free' clinical trial demonstrated that danoprevir, combined with the HCV polymerase inhibitor RG-7128 (Pharmasset Inc/Roche Holding AG), was effective in reducing HCV-RNA levels in a large proportion of treatment-naïve patients with HCV infection and in approximately half of previously non-responsive patients with HCV-1 infection, without resistance or safety concerns.
HCV Protease Inhibitors Related Prodcuts:
Daclatasvir; Daclatasvir hcl; Telaprevir; Lomibuvir; Paritaprevir; Paritaprevir dihydrate; Grazoprevir; Elbasvir; Ombitasvir; Simeprevir; Velpatasvir; Ledipasvir; Boceprevir